Browse MGH Pathology news and Pathology news from the media, links to publications, events, and Mass General videos.
The activity of four transcription factors appears to distinguish the small proportion of glioblastoma cells responsible for the aggressiveness and treatment resistance of the deadly brain tumor. The findings identify molecular circuits that may be targeted by new therapeutic approaches
MGH investigators have found that adjusting the length of the the guide RNA component of the gene-editing tools called CRISPR-Cas RNA-guided nucleases can substantially reduce the occurrence of DNA mutations at off-target sites.
A comparison of three methods of predicting recurrence risk in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of estrogen-blocking treatment.
07/16/2013: #1 in New England, #2 in the nation
U.S. News & World Report ranks Massachusetts General Hospital among the top hospitals in America based on our quality of care, patient safety and reputation in 16 specialties.
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.
MGH researchers have found a significant limitation to the use of a new gene-editing tool called CRISPR-Cas RGNs, production of unwanted DNA mutations at sites other than the desired target. Their findings indicate the need to improve the precision of the technology.
The MGH honored two staff members this month as inaugural recipients of endowed chairs in oncology, both made possible thanks to the generosity of an anonymous donor.
04/15/2013: Gene-expression signature may signify risk for recurrence, metastasis in prostate cancer
A team led by MGH researchers has identified a genetic signature that may reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed, the genetic risk index also may help distinguish tumors that require aggressive treatment from those that can safely be monitored.
Researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital have developed an imaging system enclosed in a capsule about the size of a multivitamin pill that creates detailed, microscopic images of the esophageal wall.
11/09/2012: In Memoriam: Robert E. Scully, MD
Robert E. Scully, MD, a giant in the field of pathology and a beloved member of the MGH family for more than 55 years, died Oct. 30 at the age of 91
Two MGH-led research teams and one MGH investigator have received major grants from the National Institutes of Health.
07/17/2012: Massachusetts General Hospital Ranked #1 in the Nation on U.S. News & World Report Honor Roll
Massachusetts General Hospital has moved into the number one spot on the 2012-13 U.S. News & World Report’s “America’s Best Hospitals” list.
05/25/2012: 2012 Research Scholars announced
The second group of MGH Research Scholars – recipients of unrestricted five-year grants to support innovative investigations – was announced at the hospital’s Research Advisory Council (RAC) annual meeting on May 11.
05/15/2012: All cancer cells are not created equal
A study from Massachusetts General Hospital researchers suggests that specific populations of tumor cells have different roles in the process by which tumors make new copies of themselves and grow.
Development of a new way to make a powerful tool for altering gene sequences should greatly increase the ability of researchers to knock out or otherwise alter the expression of any gene they are studying.
MGH Cancer Center investigators have defined the role of a recently identified gene abnormality – rearrangements in the ROS1 gene – in non-small-cell lung cancer, the leading cause of cancer death in the U.S. They also show that these tumors can be treated with crizotinib and describe the remarkable response of one patient to such treatment.
Investigators at the MGH Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.
12/02/2011: Bicentennial Corner
Many ‘keen minds’ have worked toward a better understanding of disease to enable improved diagnosis and treatment.
12/01/2011: Mass. General study finds amplification of multiple cell-growth genes in some brain tumors
A small percentage of the deadly brain tumors called glioblastomas, which usually resist treatment with drugs targeting mutations in cell-growth genes, appears to contain extra copies of two or three of these genes at the same time. The surprising discovery has major implications for the understanding of tumor biology and for targeted cancer therapies.
A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.
Researchers at the Wellman Center for Photomedicine at MGH have developed a one-micrometer-resolution version of the intravascular imaging technology optical coherence tomography that can reveal cellular and subcellular features of coronary artery disease.
For the first year of the MGH Research Scholars Awards program, three of the five Scholars are members of MGH-HMS Pathology and the MGH Cancer Center.
04/22/2011: Celebrating prize-winning MGH research
The presentation of the MGH's top research prizes was a highlight of the April 13 Celebration of Science, held in conjunction with the annual Scientific Advisory Committee meeting.
03/23/2011: Epigenomic findings illuminate veiled variants
Genes make up only a tiny percentage of the human genome, but the rest may hold vital clues about the genetic origins of disease. Using a new mapping strategy, a research team has begun to assign meaning to the regions beyond our genes and has revealed how minute changes in these regions might be connected to common diseases.
01/28/2011: Bicentennial Corner 1.28.11
MGH Hotline 1.18.11 MGH pathologist Reginald Fitz, MD, studied the appendix and coined the word "appendicitis" in 1886.
MGH Hotline 01.14.11 In General awards and honors
A team led by MGH researchers has developed a faster way to engineer synthetic enzymes that target specific DNA sequences for inactivation, repair or alteration.
An MGH physician-researcher and a Harvard University mathematician have collaborated to develop a mathematical model reflecting how red blood cells change during their four-month lifespan. The model uses data from routine blood tests and may be able to predict the development of anemia.
MGH Hotline 10.15.10 In General awards and honors
09/03/2010: Joung receives prestigious NIH Pioneer Award
MGH Hotline 09.03.10 J. Keith Joung, MD, PhD, of MGH Pathology, the MGH Center for Cancer Research and the Center for Computational and Integrative Biology, is one of 17 investigators nationwide to receive a 2010 National Institutes of Health (NIH) Director's Pioneer Award.
A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer.
06/03/2010: Study finds epigenetic similarities between Wilms tumor cells and normal kidney stem cells
A detailed analysis of the epigenetics – factors controlling when and where genes are expressed – of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys. These findings by MGH Cancer Center researchers reveal new cellular pathways critical for Wilms tumor development that may apply to other pediatric cancers.
Magnetic resonance spectroscopy – which analyzes the biochemistry rather than the structure of tissues – may someday be able both to pinpoint the precise location of prostate cancer and to determine the tumor's aggressiveness, information that could help guide treatment planning.
MGH Hotline 5.15.09 Two MGH scientists — Bradley Bernstein, MD, PhD, of the Department of Pathology, and Konrad Hochedlinger, PhD, of the Center for Regenerative Medicine – are among the first group of Howard Hughes Medical Institute (HHMI) Early Career Scientists.
Two MGH investigators – Bradley E. Bernstein, MD, PhD, and Konrad Hochedlinger, PhD – are among 50 receipients of the Howard Hughes Medical Institute Early Career Scientist Awards.
There are no results found in this category.
Use the search box in the upper right corner of the page to find related content.